Skip to main content

Table 3 Effect of polymyxin B in different duration, dose and medication mod on curative effect

From: Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections

Group n Effective rate (n (%)) Clearance rate (n (%))
Duration of treatment ( days)
 3–7 71 16 (16.8%) 12 (16.9%)
 8–14 57 35 (61.4%)a 32 (56.1%)a
 > 14 53 39 (73.5%)a 32 (60.4%)a
Daily dose (mg/kg/day)
 1.5 70 19 (27.1%) 25 (35.7%)
 2.0 97 46 (47.4%)b 53 (54.6%)b
2.5 14 10 (71.4%)b 11 (78.6%)b
Medication mode
 Polymyxin B monotherapy 14 3 (28.57%) 2 (14.29%)
 Polymyxin B combination 167 87 (52.1%)c 74 (44.3%)c
 Carbapenems 39 20 (51.3%) 15 (38.5%)d
 Tigecycline 61 15 (48.4%) 12 (38.7%)d
 Fosfomycin 18 10 (55.6%) 9 (50.0%)d
 Tigecycline + fosfomycin 30 19 (63.3%) 20 (66.7%)
 Carbapenems + tigecycline 17 10 (58.8%) 8 (52.9%)d
 Other 32 13 (41.9%) 10 (31.3%)d
  1. In the group of treatment duration, compared with 3–7 days group, aP < 0.05
  2. In the group of daily dose, compared with 1.5 mg/kg/days group, bP < 0.05
  3. In the group of medication mode, compared with polymyxin B monotherapy group, cP < 0.05; compared with polymyxin + tigecycline + fosfomycin group, dP < 0.05